Scandinavian Working Papers in Economics

IHE Report / IHE Rapport,
IHE - The Swedish Institute for Health Economics

No 2022:4: Cancer in Ireland – Disease Burden, Costs and Access to Medicines

Thomas Hofmarcher, Oskar Ericson and Peter Lindgren
Additional contact information
Thomas Hofmarcher: IHE - The Swedish Institute for Health Economics
Oskar Ericson: IHE - The Swedish Institute for Health Economics
Peter Lindgren: IHE - The Swedish Institute for Health Economics

Abstract: This report provides key statistics about cancer in Ireland. It builds on IHE Comparator Report 2019:7 and provides a comparison of Ireland with other selected countries in Europe. The key findings are the following:

The disease burden of cancer:

• Cancer has become the leading cause of death in Ireland over the past two decades.

• The number of newly diagnosed cancer cases in Ireland has doubled from 12,000 to 24,000 cases since 1995, driven mostly by demographic changes.

The economic burden of cancer:

• The economic burden of cancer exceeds €320 per capita per year, of which €200 are health expenditure and €120 are costs from productivity losses.

• Official aggregated data on health spending on cancer are absent in Ireland, but estimates indicate that per capita spending on cancer in Ireland is similar to the EU-15 average.

• The indirect costs of cancer have been decreasing in Ireland since 2000 due to better patient outcomes.

Outcomes of cancer patients and spending:

• Cancer survival has improved in Ireland, yet survival rates in many cancer types are lower than in other EU-15 countries resulting in hundreds of avoidable deaths every year.

• Across Europe, there is a clear pattern of countries spending more on cancer care achieving higher survival rates, which makes spending in Ireland appear less efficient.

Access to cancer medicines:

• Time to patient access of new EMA-approved cancer medicines is exceptionally long in Ireland compared with the EU-15 countries, reaching almost 2 years.

• Once reimbursed, the use of modern cancer medicines in Ireland is close to the EU-15 average, however.

• The lack of patient access to modern, effective cancer medicines in Ireland leads to a great loss in life years and quality of life of cancer patients.

Keywords: IHE; health economics; Cancer; Ireland; Epidemiology; Costs; Medicines

Language: English

68 pages, 2022

Full text files

IHE-Report-2022_4_.pdf PDF-file Full text

Download statistics

Questions (including download problems) about the papers in this series should be directed to Annette Persson Dietmann ()
Report other problems with accessing this service to Sune Karlsson ().

This page generated on 2024-02-05 17:11:53.